Deferred group - pioglitazone for Obesity

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
ObesityImmediate weight loss - Behavioral
Eligibility
18 - 55
All Sexes
What conditions do you have?
Select

Study Summary

This trial will help researchers understand how pioglitazone helps regulate insulin in obese patients, and what role abnormal proteins in fat cells play in that process.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

4 Primary · 0 Secondary · Reporting Duration: 4-9 months

4-9 months
Adipocytes
Adipocyte response to insulin - adipocyte G0S2 relative to ATGL.
Adipocyte response to insulin - perilipin 1 and FSP27 relative to HSL and ATGL
Adipocyte response to insulin - perilipin 1, ATGL and HSL phosphorylation

Trial Safety

Safety Progress

1 of 3

Trial Design

4 Treatment Groups

Deferred group - pioglitazone
1 of 4
Immediate weight loss - pioglitazone
1 of 4
Immediate weight loss - placebo
1 of 4
Deferred control group - placebo
1 of 4

Active Control

Non-Treatment Group

64 Total Participants · 4 Treatment Groups

Primary Treatment: Deferred group - pioglitazone · Has Placebo Group · Phase < 1

Deferred group - pioglitazoneActiveComparator Group · 2 Interventions: Pioglitazone, Deferred weight loss · Intervention Types: Drug, Behavioral
Immediate weight loss - pioglitazoneActiveComparator Group · 2 Interventions: Immediate weight loss, Pioglitazone · Intervention Types: Behavioral, Drug
Deferred control group - placeboPlaceboComparator Group · 2 Interventions: Deferred weight loss, Placebo · Intervention Types: Behavioral, Drug
Immediate weight loss - placeboActiveComparator Group · 2 Interventions: Immediate weight loss, Placebo · Intervention Types: Behavioral, Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 4-9 months

Who is running the clinical trial?

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,148 Previous Clinical Trials
4,074,715 Total Patients Enrolled
403 Trials studying Obesity
492,921 Patients Enrolled for Obesity
Mayo ClinicLead Sponsor
2,922 Previous Clinical Trials
3,517,089 Total Patients Enrolled
79 Trials studying Obesity
13,927 Patients Enrolled for Obesity
Michael D JensenPrincipal InvestigatorMayo Clinic
1 Previous Clinical Trials
20 Total Patients Enrolled
1 Trials studying Obesity
20 Patients Enrolled for Obesity

Eligibility Criteria

Age 18 - 55 · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
are considered healthy Non-obese adults have a BMI between 18 and 25 and are considered healthy.
People aged 18 to 55.
People with a BMI of 30 to 38 are considered obese